Climb Bio Inc (CLYM) Stock Analysis

Climb Bio Inc (CLYM) is a publicly traded company in the HEALTHCARE sector. It trades at $11.20, carries a market capitalization of $627.58M. This page summarizes the public market data, fundamentals, and frequently asked questions for CLYM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $11.20
• Market Cap: $627.58M
• EPS: $-0.77
• 52-Week High: $12.48
• 52-Week Low: $1.16

About Climb Bio Inc

Climb Bio, Inc. is a biotechnology company based in Wilmington, Delaware, specializing in the development of innovative therapies for autoimmune-driven inflammatory diseases. With a strong and diverse pipeline of drug candidates, Climb Bio harnesses advanced scientific research to address significant unmet medical needs in this therapeutic area. The company’s strategic focus on research and development, combined with its commitment to enhancing patient outcomes, establishes Climb Bio as a vit...

GNG Research Analysis

GNG Research scores Climb Bio Inc (CLYM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CLYM.

Frequently Asked Questions

Does CLYM pay dividends?

Climb Bio Inc (CLYM) does not currently pay a regular dividend.

What is CLYM's market cap?

Climb Bio Inc (CLYM) has a market capitalization of $627.58M with a current stock price of $11.20.